174 related articles for article (PubMed ID: 23757746)
21. Rosiglitazone and implications for pharmacovigilance.
Kazi D
BMJ; 2007 Jun; 334(7606):1233-4. PubMed ID: 17569897
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular safety and diabetes drug development.
Drucker DJ; Goldfine AB
Lancet; 2011 Mar; 377(9770):977-9. PubMed ID: 21316097
[No Abstract] [Full Text] [Related]
23. Insulin degludec: a novel basal insulin analogue.
Goldman-Levine JD; Patel DK; Schnee DM
Ann Pharmacother; 2013 Feb; 47(2):269-77. PubMed ID: 23386075
[TBL] [Abstract][Full Text] [Related]
24. The long Avandia endgame.
Mullard A
Lancet; 2011 Jul; 378(9786):113. PubMed ID: 21748869
[No Abstract] [Full Text] [Related]
25. [IDegLira receives extended approval].
MMW Fortschr Med; 2015 Sep; 157(15):70. PubMed ID: 26349737
[No Abstract] [Full Text] [Related]
26. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C
N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751
[No Abstract] [Full Text] [Related]
27. Use of degludec insulin in chronic complex patients.
Carretero Gómez J; Miramontes González JP; Varela Aguilar JM; Ena J; Arévalo Lorido JC;
Eur J Intern Med; 2018 Jun; 52():e27-e29. PubMed ID: 29576381
[No Abstract] [Full Text] [Related]
28. The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
Califf RM; Kramer JM
Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):782-6. PubMed ID: 18655016
[No Abstract] [Full Text] [Related]
29. Pioglitazone is a valid alternative to rosiglitazone.
Derosa G
Am J Cardiovasc Drugs; 2011 Dec; 11(6):357-62. PubMed ID: 21950735
[TBL] [Abstract][Full Text] [Related]
30. Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
Parks M; Rosebraugh C
N Engl J Med; 2010 Mar; 362(9):774-7. PubMed ID: 20164475
[No Abstract] [Full Text] [Related]
31. European Medicines Agency pledges to publish clinical reports.
Watson R
BMJ; 2014 Oct; 349():g6086. PubMed ID: 25294699
[No Abstract] [Full Text] [Related]
32. Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA.
Chong WH; Yanoff LB; Andraca-Carrera E; Thanh Hai M
N Engl J Med; 2020 Sep; 383(13):1199-1202. PubMed ID: 32966719
[No Abstract] [Full Text] [Related]
33. Experimental testing of skin reactions to insulin detemir in diabetes patients naïve to insulin detemir.
O'goshi K; Serup J; Blaaholm B; Thomsen HK; Rossing P; Tarnow L
Skin Res Technol; 2011 Nov; 17(4):411-9. PubMed ID: 21729174
[TBL] [Abstract][Full Text] [Related]
34. [Medicines for type 2 diabetes: fine tuning rather than redesign].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 2012 May; 35(5):163. PubMed ID: 22624349
[No Abstract] [Full Text] [Related]
35. Insulin detemir (levemir), a new long-acting insulin.
Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
[TBL] [Abstract][Full Text] [Related]
36. Rosiglitazone and the FDA.
Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R
N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586
[No Abstract] [Full Text] [Related]
37. Under surveillance.
Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
[No Abstract] [Full Text] [Related]
38. Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.
Pawaskar MD; Blickensderfer AL; Hoogwerf BJ; Quimbo R; Wade R
J Med Econ; 2011; 14(6):705-8. PubMed ID: 21892855
[TBL] [Abstract][Full Text] [Related]
39. Selling safety--lessons from muraglitazar.
Brophy JM
JAMA; 2005 Nov; 294(20):2633-5. PubMed ID: 16239638
[No Abstract] [Full Text] [Related]
40. The European Medicines Agency's approval of new medicines for type 2 diabetes.
Blind E; Janssen H; Dunder K; de Graeff PA
Diabetes Obes Metab; 2018 Sep; 20(9):2059-2063. PubMed ID: 29740935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
